Condition: Benzodiazepines · Bladder Cancer · Delirium · Sponsor: Peking University First Hospital
Bladder cancer is one of the most common genitourinary cancers. Transurethral resection of bladder tumor (TURBT) is the standard therapy for nonmuscle invasive bladder cancer. However, patients after TURBT are at risk for recurrence and progression. Benzodiazepines are proved to inhibit proliferation of multiple types of cancer cells in vitro. Delirium is an acute onset and transient cerebral dysfunction and is associated with worse outcomes. Previous studies indicated that benzodiazepines increase incidence of postoperative delirium. Remimazolam is a new benzodiazepine with rapid onset and ultra-short activity. The aims of this study are to explore the impact of remimazolam for general anesthesia on emergency delirium and recurrence-free survival in patients undergoing bladder cancer surgery.
This description comes directly from the study's public registry record.
Wang Dong-Xin, MD, PhD · 86 10 83572784 · wangdongxin@hotmail.com
Zhang Yu-Xiu, MD · +86 15201190755 · zhangyuxiu1992@163.com
Always discuss trial participation with your own doctor first.
| Beijing Tsinghua Chang Gung Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The Sixth Medical Center of PLA General Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University First Hospital | Beijin, Bejing, China | Recruiting |
| Guizhou Provincial People's Hospital | Guiyang, Guizhou, China | Recruiting |
| Jiangsu Provincial People's Hospital | Nanjing, Jiangsu, China | Recruiting |
| Shanghai 10th People's Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04532606